Company profile
Arcturus Therapeutics Holdings Inc.
NASDAQ: ARCT · Healthcare · Biotechnology
#371 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
49DFH 55DQ 53GM 18SS 64
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$45.4M
Rev growth YoY (TTM)
-66.4%
Net income (FY)
-$65.8M
Employees
109
as of 2026-08-13
Market cap
$216.0M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$82.0M$82.0M2025
Net income-$65.8M-$65.8M2025
Operating income-$76.3M-$76.3M2025
Total assets$271.1M$271.1M2025
Liabilities$57.2M$57.2M2025
Equity$214.0M$214.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenue82%
Grant18%
By geography
Foreign Countries100%
The read
What is Arcturus Therapeutics Holdings Inc.’s revenue?
Arcturus Therapeutics Holdings Inc. booked $82.0M in FY2025 revenue, contracting 46% year over year — slower than 80% of Healthcare companies we track, at a -80.2% net margin.
Peers · Healthcare
ARS Pharmaceuticals, Inc.41DNurix Therapeutics, Inc.53DIRadimed Corporation86AMeiraGTx Holdings plc48DDecibel Cannabis Company Inc.62CTELA Bio, Inc.47DNeighbors
San Diego →Key facts
CEOJoseph E. Payne
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: ARCT
Employees109
IPO date2013-05-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.